Timothy Fan’s, DVM, laboratory works closely with other basic scientists to evaluate novel drugs and drug delivery strategies for the treatment of cancer. He has conducted preclinical murine tumor research for over 15 years and facilitated the development of novel drugs and drug delivery strategies for improving cancer therapy. Fan has worked closely with multiple scientific researchers involved in basic and translational cancer investigations including long-term collaborator Paul Hergenrother over the past 12 years. Fan has been able to leverage companion animals as informative tumor model systems to expedite novel drug development, such as the first procaspase-3 activator, PAC-1, which has now successfully advanced to human clinical trials. Fan’s unique training as a scientist and veterinarian allows him to rapidly investigate and translate novel treatment strategies in dogs with spontaneously arising cancers and conduct meaningful comparative oncology research, which is hoped to eventually aid in treating cancer in both companion animals and human beings.